Angiogenesis inhibitors derived from thalidomide

Tomomi Noguchi, Haruka Fujimoto, Hiroko Sano, Atsushi Miyajima, Hiroyuki Miyachi, Yuichi Hashimoto

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.

Original languageEnglish
Pages (from-to)5509-5513
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume15
Issue number24
DOIs
Publication statusPublished - Dec 15 2005
Externally publishedYes

Fingerprint

Thalidomide
Angiogenesis Inhibitors
Assays
Endothelial cells
Human Umbilical Vein Endothelial Cells
Metabolites
Hydroxyl Radical
Serotonin
Derivatives
2-(2,6-diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione

Keywords

  • Angiogenesis
  • HUVEC
  • Phthalimide
  • Structural development
  • Thalidomide

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Noguchi, T., Fujimoto, H., Sano, H., Miyajima, A., Miyachi, H., & Hashimoto, Y. (2005). Angiogenesis inhibitors derived from thalidomide. Bioorganic and Medicinal Chemistry Letters, 15(24), 5509-5513. https://doi.org/10.1016/j.bmcl.2005.08.086

Angiogenesis inhibitors derived from thalidomide. / Noguchi, Tomomi; Fujimoto, Haruka; Sano, Hiroko; Miyajima, Atsushi; Miyachi, Hiroyuki; Hashimoto, Yuichi.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 15, No. 24, 15.12.2005, p. 5509-5513.

Research output: Contribution to journalArticle

Noguchi, T, Fujimoto, H, Sano, H, Miyajima, A, Miyachi, H & Hashimoto, Y 2005, 'Angiogenesis inhibitors derived from thalidomide', Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 24, pp. 5509-5513. https://doi.org/10.1016/j.bmcl.2005.08.086
Noguchi T, Fujimoto H, Sano H, Miyajima A, Miyachi H, Hashimoto Y. Angiogenesis inhibitors derived from thalidomide. Bioorganic and Medicinal Chemistry Letters. 2005 Dec 15;15(24):5509-5513. https://doi.org/10.1016/j.bmcl.2005.08.086
Noguchi, Tomomi ; Fujimoto, Haruka ; Sano, Hiroko ; Miyajima, Atsushi ; Miyachi, Hiroyuki ; Hashimoto, Yuichi. / Angiogenesis inhibitors derived from thalidomide. In: Bioorganic and Medicinal Chemistry Letters. 2005 ; Vol. 15, No. 24. pp. 5509-5513.
@article{90bf64a731b148589942263b3ef49e00,
title = "Angiogenesis inhibitors derived from thalidomide",
abstract = "5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.",
keywords = "Angiogenesis, HUVEC, Phthalimide, Structural development, Thalidomide",
author = "Tomomi Noguchi and Haruka Fujimoto and Hiroko Sano and Atsushi Miyajima and Hiroyuki Miyachi and Yuichi Hashimoto",
year = "2005",
month = "12",
day = "15",
doi = "10.1016/j.bmcl.2005.08.086",
language = "English",
volume = "15",
pages = "5509--5513",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "24",

}

TY - JOUR

T1 - Angiogenesis inhibitors derived from thalidomide

AU - Noguchi, Tomomi

AU - Fujimoto, Haruka

AU - Sano, Hiroko

AU - Miyajima, Atsushi

AU - Miyachi, Hiroyuki

AU - Hashimoto, Yuichi

PY - 2005/12/15

Y1 - 2005/12/15

N2 - 5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.

AB - 5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.

KW - Angiogenesis

KW - HUVEC

KW - Phthalimide

KW - Structural development

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=27644582508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644582508&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2005.08.086

DO - 10.1016/j.bmcl.2005.08.086

M3 - Article

C2 - 16183272

AN - SCOPUS:27644582508

VL - 15

SP - 5509

EP - 5513

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 24

ER -